Aldeyra Therapeutics (ALDX) Competitors $4.96 -0.13 (-2.55%) Closing price 04:00 PM EasternExtended Trading$5.03 +0.07 (+1.31%) As of 06:03 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALDX vs. WVE, ETNB, TLRY, PGEN, RCUS, NTLA, GPCR, XERS, ABCL, and EVOShould you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include WAVE Life Sciences (WVE), 89BIO (ETNB), Tilray Brands (TLRY), Precigen (PGEN), Arcus Biosciences (RCUS), Intellia Therapeutics (NTLA), Structure Therapeutics (GPCR), Xeris Biopharma (XERS), AbCellera Biologics (ABCL), and Evotec (EVO). These companies are all part of the "pharmaceutical products" industry. Aldeyra Therapeutics vs. Its Competitors WAVE Life Sciences 89BIO Tilray Brands Precigen Arcus Biosciences Intellia Therapeutics Structure Therapeutics Xeris Biopharma AbCellera Biologics Evotec WAVE Life Sciences (NASDAQ:WVE) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Which has preferable valuation & earnings, WVE or ALDX? Aldeyra Therapeutics has lower revenue, but higher earnings than WAVE Life Sciences. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Aldeyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioWAVE Life Sciences$108.30M10.02-$97.01M-$0.90-7.58Aldeyra TherapeuticsN/AN/A-$55.85M-$0.85-5.84 Does the media refer more to WVE or ALDX? In the previous week, WAVE Life Sciences had 2 more articles in the media than Aldeyra Therapeutics. MarketBeat recorded 3 mentions for WAVE Life Sciences and 1 mentions for Aldeyra Therapeutics. WAVE Life Sciences' average media sentiment score of 1.02 beat Aldeyra Therapeutics' score of 0.95 indicating that WAVE Life Sciences is being referred to more favorably in the media. Company Overall Sentiment WAVE Life Sciences Positive Aldeyra Therapeutics Positive Do institutionals & insiders believe in WVE or ALDX? 89.7% of WAVE Life Sciences shares are owned by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are owned by institutional investors. 24.0% of WAVE Life Sciences shares are owned by insiders. Comparatively, 8.5% of Aldeyra Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Which has more risk and volatility, WVE or ALDX? WAVE Life Sciences has a beta of -1.15, suggesting that its share price is 215% less volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Do analysts rate WVE or ALDX? WAVE Life Sciences presently has a consensus target price of $20.33, suggesting a potential upside of 198.14%. Aldeyra Therapeutics has a consensus target price of $9.50, suggesting a potential upside of 91.53%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Aldeyra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score WAVE Life Sciences 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93Aldeyra Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is WVE or ALDX more profitable? Aldeyra Therapeutics' return on equity of -73.63% beat WAVE Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets WAVE Life SciencesN/A -78.45% -41.51% Aldeyra Therapeutics N/A -73.63%-50.61% SummaryWAVE Life Sciences beats Aldeyra Therapeutics on 9 of the 14 factors compared between the two stocks. Get Aldeyra Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALDX vs. The Competition Export to ExcelMetricAldeyra TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$304.87M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E Ratio-5.8423.4975.8626.51Price / SalesN/A672.77528.72123.58Price / CashN/A169.4937.1760.46Price / Book4.175.3312.796.29Net Income-$55.85M$32.95M$3.28B$270.51M7 Day Performance-13.89%-0.44%0.22%2.15%1 Month Performance-7.98%3.91%4.61%6.35%1 Year Performance-16.07%-3.07%68.33%25.48% Aldeyra Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALDXAldeyra Therapeutics2.0091 of 5 stars$4.96-2.6%$9.50+91.5%-15.6%$304.87MN/A-5.8410Positive NewsWVEWAVE Life Sciences4.3198 of 5 stars$7.58-8.6%$20.33+168.2%+18.9%$1.32B$108.30M-8.42240Positive NewsETNB89BIO2.6251 of 5 stars$8.57-3.4%$28.00+226.7%-5.4%$1.32BN/A-2.3740Positive NewsAnalyst ForecastTLRYTilray Brands2.9959 of 5 stars$1.12-5.9%$1.94+73.0%-32.2%$1.31B$821.31M-0.482,842Positive NewsPGENPrecigen4.5534 of 5 stars$4.16-4.6%$8.25+98.3%+241.9%$1.30B$4.34M-9.90190Positive NewsRCUSArcus Biosciences1.867 of 5 stars$11.43-6.3%$21.14+85.0%-35.5%$1.30B$258M-3.60500Positive NewsNTLAIntellia Therapeutics4.4501 of 5 stars$11.84-1.8%$29.05+145.4%-47.6%$1.29B$57.88M-2.52600GPCRStructure Therapeutics3.453 of 5 stars$20.86-5.5%$75.71+263.0%-50.5%$1.27BN/A-19.87136Positive NewsXERSXeris Biopharma2.7861 of 5 stars$7.77-1.0%$7.08-8.8%+155.6%$1.27B$203.07M-37.00290Positive NewsABCLAbCellera Biologics2.6454 of 5 stars$4.17-1.2%$8.00+91.8%+58.2%$1.26B$28.83M-7.58500News CoverageEVOEvotec1.6833 of 5 stars$3.49+0.3%$5.40+54.7%-1.1%$1.24B$862.40M0.004,827News CoverageGap Up Related Companies and Tools Related Companies WVE Competitors ETNB Competitors TLRY Competitors PGEN Competitors RCUS Competitors NTLA Competitors GPCR Competitors XERS Competitors ABCL Competitors EVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALDX) was last updated on 9/16/2025 by MarketBeat.com Staff From Our PartnersClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aldeyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aldeyra Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
